Summit Global Investments bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 45,425 shares of the biotechnology company's stock, valued at approximately $779,000.
Other institutional investors also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in ADMA Biologics by 13.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock worth $13,171,000 after acquiring an additional 80,400 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of ADMA Biologics during the third quarter valued at approximately $61,858,000. Raymond James Financial Inc. bought a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $19,076,000. EWG Elevate Inc. purchased a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $480,000. Finally, Citigroup Inc. increased its position in ADMA Biologics by 251.7% during the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after buying an additional 277,138 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.
Check Out Our Latest Research Report on ADMA Biologics
ADMA Biologics Stock Down 2.6 %
ADMA stock traded down $0.52 during midday trading on Wednesday, hitting $19.70. The company's stock had a trading volume of 2,180,350 shares, compared to its average volume of 3,363,059. The firm's 50-day moving average is $16.97 and its 200-day moving average is $18.11. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 12 month low of $5.90 and a 12 month high of $23.64. The company has a market cap of $4.66 billion, a PE ratio of 70.36 and a beta of 0.60.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
